TIDMMEDG 
 
 
Medgenics Inc 
05 July 2010 
 
? 
                                Medgenics, Inc. 
                         ('Medgenics' or the 'Company') 
                  Statement  Regarding Share Price Discrepancy 
Medgenics (AIM: MEDG and MEDU), the company that has developed a novel 
technology for the manufacture and delivery of therapeutic proteins continuously 
in patients using their own tissue, has noted the widening discrepancy between 
the mid-market price of the MEDU and MEDG quotes for common shares of par value 
US $0.0001 each in the Company ("Common Shares"). 
The Company would like to confirm that all of its issued and outstanding Common 
Shares, whether trading on the MEDU line or the MEDG line, rank pari passu in 
all respects and carry equal voting rights and equal rights to dividends. The 
only difference between the two quotes (MEDU and MEDG) is that the Common Shares 
trading on the MEDG line were when issued and remain subject to restrictions on 
transfer under the US Securities Act of 1933 (as amended) (the "US Securities 
Act").  The MEDG line of Common Shares cannot be settled electronically in the 
CREST system and, instead, settle in CREST only on a cash basis, with the buyer 
being responsible for re-registering the certificated holding.  Buyers and 
sellers of the MEDG line of stock are both required to complete a representation 
letter in connection with a dealing in Common Shares trading on the MEDG line in 
order to assure compliance with the transfer restrictions and for settlement to 
be facilitated.  A significant number of the Common Shares trading on the MEDG 
line may now qualify to have the restrictions lifted and for migration to the 
MEDU line of Common Shares. 
Other than the transfer restrictions, the Company confirms that there are no 
differences in rights between the Common Shares quoted on the MEDU line and 
those quoted on the MEDG line. 
For further information regarding the applicable restrictions on transfer on 
MEDG quoted Common Shares, the ability to transfer Common Shares from the MEDG 
line onto the MEDU line, participation in the depository interest arrangements 
that have been established by the Company and the transfer of Common Shares 
within CREST, shareholders should refer to the announcement made by the Company 
on 12 November 2008 or contact the Company directly at 
investor-relations@medgenics.com. 
 
For further information, contact: 
 
Andrew Pearlman                                             +972 4 902 8900 
CEO Medgenics, Inc 
 
Mike Wort / Anna Dunphy                            +44 207 861 3838 
De Facto Communications (PR) 
 
James Pinner / Derek Crowhurst                    +44 207 444 0800 
Religare Capital Markets (Nomad) 
 
Ian Callaway / Alex Mattey                            +44 207 638 5600 
SVS Securities plc (Joint Broker) 
 
Jonathan Senior                                               +44 207 776 1219 
Nomura Code (Joint Broker) 
 
 
Notes to Editors: 
About Medgenics: 
Medgenics is a commercial -stage biopharmaceutical company developing its unique 
tissue-based Biopump platform technology to provide sustained-action protein 
therapy for the treatment of a range of chronic diseases. The first revenue 
generating commercial deal with a well known multinational pharmaceutical 
company was negotiated in late 2009. 
Biopumps are made using needle biopsies taken from the lower layer of the 
patient's skin under local anaesthetic and processed during 10-14 days to become 
30 mm long tissue biofactories producing the required protein.  The requisite 
number of Biopumps are injected under the patient's skin to provide sustained 
protein production and delivery for many months. The Company is developing the 
Biopump to provide substantially greater safety and reliability in protein 
treatment in a more cost effective manner than experienced with the existing 
injected protein therapies.  Medgenics currently has three products in 
development based on this technology and addressing the indications of: 
 
- Anaemia - using EPODURE, a Biopump producing erythropoietin (EPO) 
- Hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a) 
- Haemophilia - using a Biopump to produce clotting Factor VIII 
The Company's Phase I/II clinical trial using EPODURE to treat anaemia in 
patients with chronic kidney disease, has demonstrated proof of concept of the 
Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for 
six months or more, EPODURE Biopumps have already provided effective anaemia 
treatment in most of these patients for 6-12 months, even at the low 
administered dose. 
Medgenics intends to develop its innovative products and bring them to market 
via multiple strategic partnerships with major pharmaceutical and/or medical 
device companies. In addition to treatments for Anaemia, Hepatitis-C, and 
Haemophilia, Medgenics plans to develop and/or out-license a pipeline of future 
Biopump products targeting the large and rapidly growing global protein therapy 
market, which is forecast to reach US $87 billion by the end of 2010. Other 
potential applications of Biopumps producing various proteins include multiple 
sclerosis, arthritis, pediatric growth hormone deficiency, obesity, and 
diabetes. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRARIMFTMBIMBTM
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Medgenics(Regs) Charts.
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Medgenics(Regs) Charts.